TNYA

In May 2026, Tenaya reported its Q1 2026 financial results, including a Q1 loss and revenue that missed estimates, and announced an expanded research collaboration with Alnylam Pharmaceuticals. In April 2026, Tenaya announced a late-breaking oral presentation of new clinical data from the RIDGE™-1 Phase 1b/2 clinical trial of TN-401 gene therapy at ASGCT 2026. In March 2026, the company reported Fourth Quarter and Full Year 2025 financial results and presented preclinical data at MDA 2026 highlighting TN-301's potential in Duchenne muscular dystrophy. In December 2025, Tenaya reported positive initial data from the RIDGE-1 Phase 1b/2 clinical trial of TN-401, the FDA removed a clinical hold on the MyPEAK-1™ Phase 1b/2a clinical trial of TN-201, and the company completed an underwritten public offering of units, raising approximately $60 million. In November 2025, Tenaya presented promising data from the MyPEAK-1 Phase 1b/2 clinical trial for TN-201.